{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["196"],"submitter":["Xing Y"],"pubmed_abstract":["To administer vitamin C (VC) with precision to patients with the coronavirus disease (COVID-19), we developed an ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method to assess plasma VC concentrations. 31 patients with COVID-19 and 51 healthy volunteers were enrolled. VC stability was evaluated in blood, plasma, and precipitant-containing stabilizers. A proportion of 7.7 % of VC was degraded in blood at room temperature (RT) (approximately 20-25 °C) at 1.5 h post administration with respect to the proportion degraded at 0.5 h, but without statistical difference. VC was stable in plasma for 0.75 h at RT, 2 h at 4 °C, 5 days at -40 °C, and 4 h in precipitant-containing stabilizer (2 % oxalic acid) at RT. The mean plasma concentration of VC in patients wit"],"journal":["Journal of pharmaceutical and biomedical analysis"],"pagination":["113927"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7839397"],"repository":["biostudies-literature"],"pubmed_title":["Vitamin C supplementation is necessary for patients with coronavirus disease: An ultra-high-performance liquid chromatography-tandem mass spectrometry finding."],"pmcid":["PMC7839397"],"pubmed_authors":["Guo M","Zhu Z","Ling Y","Gao M","Zhao B","He J","Lu H","Xing Y","Mao E","Zhang L","Yin L","Shi H"],"additional_accession":[]},"is_claimable":false,"name":"Vitamin C supplementation is necessary for patients with coronavirus disease: An ultra-high-performance liquid chromatography-tandem mass spectrometry finding.","description":"To administer vitamin C (VC) with precision to patients with the coronavirus disease (COVID-19), we developed an ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method to assess plasma VC concentrations. 31 patients with COVID-19 and 51 healthy volunteers were enrolled. VC stability was evaluated in blood, plasma, and precipitant-containing stabilizers. A proportion of 7.7 % of VC was degraded in blood at room temperature (RT) (approximately 20-25 °C) at 1.5 h post administration with respect to the proportion degraded at 0.5 h, but without statistical difference. VC was stable in plasma for 0.75 h at RT, 2 h at 4 °C, 5 days at -40 °C, and 4 h in precipitant-containing stabilizer (2 % oxalic acid) at RT. The mean plasma concentration of VC in patients wit","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2026-05-07T19:22:08.215Z","creation":"2026-04-07T23:13:29.429Z"},"accession":"S-EPMC7839397","cross_references":{"pubmed":["33549875"],"doi":["10.1016/j.jpba.2021.113927"]}}